烯醇化酶-α和C-MYC启动子结合蛋白-1基于PI3K/Akt通路调控肝细胞癌发生发展的研究进展  

Research progress of enolase-α and C-MYC promoter binding protein-1 regulating the occurrence and progression of hepatocellular carcinoma based on PI3K/Akt pathway

作　　者：徐伟鑫 王春芳[1] 罗艳红[1] XU Weixin;WANG Chunfang;LUO Yanhong(School of Laboratory Medicine,Youjiang Medical University for Nationalities,Guangxi Zhuang Autonomous Region,Baise533000,China)

机构地区：[1]右江民族医学院医学检验学院,广西百色533000

出　　处：《中国医药导报》2022年第19期53-56,共4页China Medical Herald

基　　金：国家自然科学基金资助项目(81960303);右江民族医学院校级科研课题(yy2021sk012)。

摘　　要：烯醇化酶-α(ENO1)是一种具有组织特异性表达的糖酵解关键酶,其参与糖酵解并影响此进程,C-MYC启动子结合蛋白-1(MBP-1)可抑制癌基因C-MYC的表达。目前发现,两者由同一基因编码表达,并且其表达调控与PI3K/Akt通路有着复杂的关系。ENO1和MBP-1可通过调控PI3K/Akt通路,在肝细胞癌(HCC)等肿瘤的进展和抑制中发挥重要作用。本文就ENO1和MBP-1的功能、表达调控、与PI3K/Akt通路的关系及基于该通路对HCC等癌症的作用机制进行简要综述,从而为HCC发生和进展的可能分子机制和可用于调控该机制的分子靶点提供一定的理论依据,并且为未来对于HCC的有效治疗提供新思路。Enolase-α(ENO1) is a type of key glycolysis enzyme with tissue-specific expression, which participates in glycolysis and affects the process of glycolysis. C-MYC promoter binding protein-1(MBP-1) can inhibit the expression of oncogene C-MYC. At present, it has been found that they are expressed by the same genetic encode, and there is a complex relationship between their expression regulation and the PI3K/Akt pathway. ENO1 and MBP-1 play an important role in the progression and inhibition of tumors such as hepatocellular carcinoma(HCC) by regulating the PI3K/Akt pathway. This paper briefly reviewes the function of ENO1 and MBP-1, their expression regulation, and their relationship with PI3K/Akt signal pathway as well as the mechanism of this pathway on HCC. Thus we can explore possible molecular mechanism for the occurrence and progression of HCC so as to provide a theoretical basis for molecular targets to regulate this mechanism. It aims to provide new ideas for the effective treatment of HCC in the future.

关 键 词：烯醇化酶-α C-MYC启动子结合蛋白-1 PI3K/AKT通路 肝细胞癌 

分 类 号：R735.7[医药卫生—肿瘤]